NESS ZIONA, Israel (February 24, 2014) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that Company management will ring the Opening Bell at The NASDAQ MarketSite in Times Square, New York at 9:30 a.m. ET on Tuesday, February 25, 2014.
David Tsur, Co-Founder and Chief Executive Officer, along with Gil Efron, Chief Financial Officer, and Pnina Strauss, Vice President-Clinical Development and IP, will perform the honorary bell-ringing ceremony that will be held from 9:15 to 9:30 a.m. ET. A live webcast will be available at http://new.livestream.com/nasdaq/live.
"We are honored to be ringing The NASDAQ Opening Bell. Since our U.S. listing in 2013, the NASDAQ has enabled us to trade alongside some of the world's leading technology companies and enhanced the Company's visibility in the U.S. capital markets. In addition, trading on the world's largest global trading platform has increased our exposure to a variety of business opportunities and heightened awareness of Kamada as we advance the development of innovative therapeutics to address unmet medical needs in rare and orphan diseases,” noted Mr. Tsur.
About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly purified, liquid form, as well as other plasma-derived proteins. AAT is a protein derived from human plasma with known and newly discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company's flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership with Baxter International. In addition to Glassia, Kamada has a product line of nine other injectable pharmaceutical products that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America, Eastern Europe and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that completed pivotal Phase 2/3 clinical trials in Europe and will be entering Phase 2 clinical trials in the U.S. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing 10 complementary products in Israel that are manufactured by third parties.
Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements that involve risks, uncertainties and assumptions, such as statements regarding assumptions and results related to financial results forecast, commercial results, clinical trials, the EMA and US FDA authorizations and timing of clinical trials. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the US FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays. The forward-looking statements made herein speak only as of the date of this release and the Company undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Contacts:
Gil Efron
CFO
ir@kamada.com
Anne Marie Fields
212-838-3777
afields@lhai.com